Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

180.62
-1.1800-0.65%
Post-market: 180.620.00000.00%19:27 EDT
Volume:1.08M
Turnover:194.81M
Market Cap:11.12B
PE:-30.93
High:184.00
Open:181.93
Low:179.16
Close:181.80
52wk High:198.00
52wk Low:95.49
Shares:61.56M
Float Shares:58.65M
Volume Ratio:1.54
T/O Rate:1.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8403
EPS(LYR):-5.8403
ROE:-8.47%
ROA:5.22%
PB:2.57
PE(LYR):-30.93

Loading ...

Jazz Pharmaceuticals Appoints Ted W. Love, M.d., to Its Board of Directors

THOMSON REUTERS
·
Oct 29, 2025

Press Release: Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors

Dow Jones
·
Oct 29, 2025

Jazz Pharmaceuticals price target lowered to $199 from $204 at JPMorgan

TIPRANKS
·
Oct 27, 2025

Jazz Pharmaceuticals Plc : Needham Raises Target Price to $210 From $202

THOMSON REUTERS
·
Oct 24, 2025

U.S. RESEARCH ROUNDUP-Avery Dennison, Expedia Group, Hologic

Reuters
·
Oct 23, 2025

Jazz Pharmaceuticals plc to Announce Third Quarter 2025 Results

Reuters
·
Oct 23, 2025

Avadel, Jazz Pharmaceuticals End Patent Dispute With Settlement

Dow Jones
·
Oct 22, 2025

Avadel Pharmaceuticals and Jazz Pharmaceuticals Reach Global Settlement

THOMSON REUTERS
·
Oct 22, 2025

Avadel Pharmaceuticals: Lumryz 10% of Net Sales Royalty Until Feb 18, 2036

THOMSON REUTERS
·
Oct 22, 2025

Avadel Pharmaceuticals: From No Earlier Than Mar 1 2028, Lumryz Sold for Any Future FDA Approved Indication to Be Subject to 10% of Net Sales Royalty

THOMSON REUTERS
·
Oct 22, 2025

Avadel Pharmaceuticals Plc - to Pay Jazz 3.85% Royalties on Lumryz Sales Until 2036

THOMSON REUTERS
·
Oct 22, 2025

Jazz Pharmaceuticals Has Upside Potential in Oncology Pipeline Revenue, Morgan Stanley Says

MT Newswires Live
·
Oct 20, 2025

Morgan Stanley Raises Price Target on Jazz Pharmaceuticals to $180 From $167, Keeps Overweight Rating

MT Newswires Live
·
Oct 20, 2025

Jazz Pharmaceuticals Plc : Morgan Stanley Raises Target Price to $180.00 From $167.00

THOMSON REUTERS
·
Oct 20, 2025

3 Small Cap Stocks To Play As The Bantamweights Break Out On Wall Street

Benzinga_recent_news
·
Oct 18, 2025

Praxis Precision's tremor-drug trial has succeeded where others have failed. The stock is skyrocketing.

Dow Jones
·
Oct 17, 2025

Pharma Mar Receives $50 Mln From Jazz Pharmaceuticals For FDA Approval Of Zepzelca In Combination With Atezolizumab

Reuters
·
Oct 15, 2025

Ionis, Jazz Named Top Picks as US Biopharma Heads Into Steady Q3, BofA Says

MT Newswires Live
·
Oct 09, 2025

BofA Adjusts Price Target on Jazz Pharmaceuticals Public to $230 From $225

MT Newswires Live
·
Oct 09, 2025

Jazz Pharmaceuticals price target raised to $230 from $225 at BofA

TIPRANKS
·
Oct 09, 2025